Sunshine Biopharma Operating Expenses Growth & History (SBFM)
Sunshine Biopharma's operating expenses was $18.5M for fiscal 2025.
View full Sunshine Biopharma company overviewSunshine Biopharma annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.5M | $2.0M | +12.14% |
| 2024 | 2024-12-31 | $16.5M | $3.4M | +25.58% |
| 2023 | 2023-12-31 | $13.1M | −$15.6M | −54.27% |
| 2022 | 2022-12-31 | $28.7M | $26.1M | +1025.06% |
| 2021 | 2021-12-31 | $2.6M | $1.9M | +309.80% |
| 2020 | 2020-12-31 | $622,437 | −$29,270 | −4.49% |
| 2019 | 2019-12-31 | $651,707 | −$512,583 | −44.03% |
| 2018 | 2018-12-31 | $1.2M | $307,100 | +35.83% |
| 2017 | 2017-12-31 | $857,190 | — | — |
Sunshine Biopharma quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.0M | −$1.4M | −26.25% |
| Q1 2026 | 2026-03-31 | $3.6M | −$449,589 | −11.17% |
| Q4 2025 | 2025-12-31 | $4.8M | −$361,096 | −6.97% |
| Q3 2025 | 2025-09-30 | $4.2M | $187,649 | +4.72% |
| Q2 2025 | 2025-06-30 | $5.5M | $1.9M | +51.12% |
| Q1 2025 | 2025-03-31 | $4.0M | $321,250 | +8.67% |
| Q4 2024 | 2024-12-31 | $5.2M | $1.4M | +38.84% |
| Q3 2024 | 2024-09-30 | $4.0M | $1.2M | +43.43% |
| Q2 2024 | 2024-06-30 | $3.6M | $657,898 | +22.18% |
| Q1 2024 | 2024-03-31 | $3.7M | $47,823 | +1.31% |
| Q4 2023 | 2023-12-31 | $3.7M | −$21.1M | −84.99% |
| Q3 2023 | 2023-09-30 | $2.8M | $984,725 | +55.17% |
| Q2 2023 | 2023-06-30 | $3.0M | $2.2M | +284.57% |
| Q1 2023 | 2023-03-31 | $3.7M | $2.4M | +184.34% |
| Q4 2022 | 2022-12-31 | $24.9M | $24.6M | +8090.45% |
| Q3 2022 | 2022-09-30 | $1.8M | $1.3M | +238.63% |
| Q2 2022 | 2022-06-30 | $771,420 | $348,463 | +82.39% |
| Q1 2022 | 2022-03-31 | $1.3M | −$11,020 | −0.85% |
| Q4 2021 | 2021-12-31 | $303,460 | −$57,408 | −15.91% |
| Q3 2021 | 2021-09-30 | $527,129 | $449,031 | +574.96% |
| Q2 2021 | 2021-06-30 | $422,957 | $284,404 | +205.27% |
| Q1 2021 | 2021-03-31 | $1.3M | $1.3M | +2787.89% |
| Q4 2020 | 2020-12-31 | $360,868 | $138,675 | +62.41% |
| Q3 2020 | 2020-09-30 | $78,098 | −$126,575 | −61.84% |
| Q2 2020 | 2020-06-30 | $138,553 | $70,783 | +104.45% |
| Q1 2020 | 2020-03-31 | $44,918 | −$112,153 | −71.40% |
| Q4 2019 | 2019-12-31 | $222,193 | $84,285 | +61.12% |
| Q3 2019 | 2019-09-30 | $204,673 | −$84,152 | −29.14% |
| Q2 2019 | 2019-06-30 | $67,770 | −$512,741 | −88.33% |
| Q1 2019 | 2019-03-31 | $157,071 | $25 | +0.02% |
| Q4 2018 | 2018-12-31 | $137,908 | — | — |
| Q3 2018 | 2018-09-30 | $288,825 | $175,020 | +153.79% |
| Q2 2018 | 2018-06-30 | $580,511 | $108,293 | +22.93% |
| Q1 2018 | 2018-03-31 | $157,046 | — | — |
| Q3 2017 | 2017-09-30 | $113,805 | — | — |
| Q2 2017 | 2017-06-30 | $472,218 | — | — |
Sunshine Biopharma operating expenses trends
Over the last five fiscal years, Sunshine Biopharma's operating expenses increased from $622,437 to $18.5M, a change of $17.9M. The latest reported quarter, Q2 2026, shows $4.0M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sunshine Biopharma source filings ↗